P57. Activation of RIG-I induces immunogenic cell death

Background The interaction between the immune system and cancer cells has become a focus of recent cancer therapy research. Immunogenic cell death, short ICD, was described as a cell death modality that stimulates an immune response against dead-cell antigens, in particular when they derive from cancer cells. Most malignant cells are poorly immunogenic and fail to elicit an effective antitumour immune response. Certain anti-cancer treatments, however, have been shown to induce ICD and transform cancer cells into potent inducers of an anti-cancer immune response. An important component is the induction of a specific cytotoxic T-cell response driven by DCs that have engulfed and processed tumour antigens. Recently, we have shown that the RIG-I ligand 3pRNA induces tumosr cell death in vitro and in vivo. Whether and how 3pRNA induced tumour cell death leads to a specific antitumor response is unknown. Here we analyse the immunogenicity of RIG-I induced tumour cell death in vitro and in vivo.